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Abstract
Background: Over 290,000 patients are undergoing hemodialysis (HD) in Japan. With old age, the odds of
undergoing HD treatment sharply increase, as does the prevalence of cognitive impairment. The aim of the
present work was to assess cognitive impairment in HD patients and its relation to clinical characteristics.
Methods: Using a cross-sectional design, we administered the Mini-Mental State Examination (MMSE) to 154 HD
outpatients and 852 participants from the Iwaki Health Promotion Project 2010, representing the general
population.
Results: The prevalence of cognitive impairment based on the MMSE was 18.8% in HD patients. HD patients
showed a higher prevalence of cognitive impairment in older groups (50 years and older). In a logistic regression
model with age, gender and amount of education as covariates, undergoing HD was a significant independent
factor (OR = 2.28, 95% CI 1.33 to 3.94) associated with a lower MMSE score. Among HD patients, we found that
level of education was associated with MMSE score.
Conclusions: There is a high prevalence of cognitive impairment among HD patients that has adverse implications
for hospitalization and shortens their life expectancy. HD treatment was an independent risk factor for cognitive
impairment. Clinicians should carefully monitor and treat cognitive impairment in HD patients. Further studies are
required to determine the reasons for cognitive impairment in HD patients.
Introduction
Advances in medical technology and improvements in
public health have brought about a progressive increase
in the population undergoing hemodialysis (HD). Over
290,000 patients receive HD in Japan, which has the
world’s highest rate of dialysis treatment (2,280 per mil-
lion people) as of December 2009 [1]. The prevalence of
HD treatment sharply increases in old age, as does the
prevalence of cognitive impairment.
Recently, the relationship between HD and cognitive
impairment has attracted attention [2-5], and its causes
have been discussed. A previous study [3] of 80 HD
patients (mean age, 61.2 ± 14.3 years) found severe
levels of impairment in executive function (38%), as
measured by the Trail Making Test B, Part B (Trails B),
and severe memory impairment (33%) based on the
s h o r tf o r mo ft h eC a l i f o r n i aV e r b a lL e a r n i n gT r i a l
(CVLT). A more recent study [4] assessing cognitive
function across multiple cognitive domains in 338 HD
patients (mean age, 71.2 ± 9.5 years) showed that the
37% of patients had severe cognitive impairment. In
older HD patients, a French study [6] showed that the
prevalence of cognitive impairment based on the Mini-
Mental State Examination (MMSE) was 47% of 51 HD
outpatients (at least 70 years old).
The etiology of cognitive impairment among HD
patients is thought to be multifactorial, and includes fac-
tors such as cerebrovascular lesion [7,8], hypotension
[9,10], abnormalities of serological data [2,11], social his-
tory [12] and amount of HD [3,13]. In addition, the high
prevalence of cardiovascular risk factors might oversha-
dow the roles of aging and non-vascular factors in the
development of cognitive impairment [14-16].
There have only been a few studies [3,4,17] that com-
pared the features of cognitive function between HD
patients and the non-HD population. It is therefore
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any medium, provided the original work is properly cited.necessary to accurately assess the features of cognitive
function cross-sectionally, especially in comparison with
a healthy reference group.
In this study, we assessed the risk factors for cognitive
impairment in HD patients and investigated the preva-
lence of cognitive impairment among HD patients com-
p a r e dw i t ht h a to ft h eg e n e r a lp o p u l a t i o ni nJ a p a n .T o
the best of our knowledge, this is the largest study to
date to assess the effect of HD on cognitive function
and the first report comparing HD patients with the
general population in Japan.
Methods
Participants
This study was conducted between September 2009 and
January 2010. A total of 154 patients (88 males and 66
females) undergoing HD were recruited at Oyokyo Kid-
ney Research Institute in Japan. Demographic data (age,
gender, amount of education) were obtained from self-
questionnaires and interviews. Clinical information
(duration of hemodialysis, dry weight) was obtained
from medical charts. Blood sampling was performed no
later than 2 weeks prior to cognitive assessment. Red
blood cell count, albumin, sodium, potassium, uric acid,
creatinine, blood urea nitrogen and amount of hemodia-
lysis were also measured by standard analytical techni-
ques. As a reference group, 852 healthy volunteers (314
males and 538 females, aged 30 years and above) who
participated in the Iwaki Health Promotion Project 2008
were also included. The data collection for this study
was approved by the Ethics Committee of the Hirosaki
University School of Medicine and all subjects provided
written informed consent before participating in this
study.
Assessment of cognitive impairment
The MMSE [18] was given to all participants to measure
their global cognitive status. This test assesses orienta-
tion to place and time, short-term memory, episodic
long-term memory, subtraction, ability to construct a
sentence and oral language ability. The maximum score
was set as 30 and poor cognition was defined as a score
of less than 24 [19].
Statistical analysis
Data are presented as mean ± SD. A value of P <0.05
was considered significant. The unpaired Student’s t test
was performed to analyze continuous variables, and a c
2
test or Fisher’s exact test was performed to analyze cate-
gorical variables. Although we divided the subjects into
age subgroups by decades, the age-specific prevalence of
a lower MMSE score was analyzed across three larger
groups (30-49, 50-69 and 70+ years old) due to the
small sample size of each smaller subgroup. To assess
the relationship between undergoing HD and poor cog-
nitive function, a logistic regression analysis was per-
formed after adjusting for confounding factors (age,
gender and amount of education). In addition, a logistic
regression analysis was also applied to determine the
factors associated with MMSE score among the HD
patient group. The data were analyzed using the PASW
Statistics software (version 18.0.0) for Windows (SPSS
Inc., Chicago, IL, USA).
Results
Clinical and demographic characteristics of the subjects
The prevalence of cognitive impairment based on the
M M S Es c o r ew a s1 8 . 8 %a m o n gH Dp a t i e n t sa n d6 . 0 %
among control. Table 1 shows the clinical and demo-
graphic characteristics among the subjects. Compared
with the controls, the HD patients were older, had less
education and had lower MMSE scores.
Risk factors associated with having lower MMSE scores
(<24)
Table 2 shows the age-specific prevalence of lower
MMSE (<24) among patients with HD and the general
population in Japan. HD patients showed a higher pre-
valence in the older groups (50-69, 70+ years old) but
not in the youngest group (30-49 years old). The effect
Table 1 Clinical and demographic characteristics of study
subjects
Patients on
hemodialysis
n = 154
Controls
n = 852
P
value
Age 65.1 ± 13.3 57.8 ±
12.2
0.001
Gender M 88, F 66 M 314, F
538
0.001
Duration of education
(years)
10.7 ± 2.5 11.3 ± 2.1 0.01
MMSE score 26.6 ± 3.9 28.1 ± 2.4 0.001
Duration of hemodialysis
(years)
7.8 ± 6.4
Erythrocyte count (10
4/
mm
3)
353.0 ± 41.2
Albumin (g/dl) 3.7 ± 0.4
Sodium (mEq/l) 139.1 ± 3.4
Potassium (mEq/l) 4.8 ± 0.8
Uric acid (mg/dl) 7.6 ± 1.4
Creatinine (mg/dl) 10.7 ± 3.2
Blood urea nitrogen (mg/
dl)
62.1 ± 15.8
Dry weight (kg) 55.1 ± 13.9
Amount of hemodialysis
(Kt/V)
1.83 ± 4.50
Data are presented as mean ± SD.
*Indicates a significant difference (P < 0.05) between groups.
MMSE = Mini-Mental State Examination.
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(<24) is shown in Tables 3 and 4, respectively. In a
logistic regression model with age gender and amount
of education as covariates (Table 5), undergoing HD
was a significant independent factor (odds ratio = 2.28)
having poor cognitive function.
Factors that influenced the MMSE scores among HD
patients
T h er e s u l t so fal o g i s t i cr e g ression model that included
age, gender, amount of education, duration of hemodia-
lysis, red blood cell count, albumin, sodium, potassium,
uric acid, creatinine, blood urea nitrogen, dry weight,
amount of hemodialysis, and comorbidities are shown in
Table 6. Amount of education was independently and
significantly associated with the MMSE score. Serum
sodium concentration, dry weight and having cerebro-
vascular disease approached statistical significance (P <
0.10).
Discussion
In Japan, the mean age of HD patients has changed con-
siderably over time, from 48.3 years old in 1983 to 65.8
years old in 2009 [1]. Aging is associated with cognitive
impairment, which can cause various behavioral and
psychological symptoms [20]. In patients undergoing
HD, cognitive impairment brings more serious conse-
quences, such as hospitalization and reduced life expec-
tancy [11,21]. Cognitive impairment in HD patients
might hinder them from complying with dialysis sche-
dules, medications, and dietary restrictions.
In this study, 18.8% of HD patients were classified as
having cognitive impairment. Among those who were 50
years or older, the prevalence of cognitive impairment
was higher among HD patients than among the con-
trols. We also found that HD patients had higher risk
for poor cognitive function even after adjusting for cov-
ariates. Among HD patients, level of education was
associated with MMSE score. In addition, serum sodium
level, dry weight and history of cerebrovascular disease
tended to associate with MMSE score of HD patients.
Table 2 shows the age-specific prevalence of lower
MMSE scores (<24) in HD patients and in the control
group. First, we divided the subjects into age subgroups
by decade. However, these groups were then integrated
into three larger groups (30-49, 50-69 and at least 70
years old) to analyze the effect of aging because of the
small sample size, which caused wide variability in the
performance of each subgroup. There was little differ-
ence among the younger groups. However, in the older
age group, the HD patients had a higher prevalence of
cognitive impairment than did the controls. A possible
explanation is that the failure to find a difference in the
prevalence of cognitive impairment in those aged 49
years and younger is due to the smaller sample size of
this group. There might be insufficient power to detect
associations within such a small group. Therefore we
could not rule out the possibility of beta errors affecting
our results.
The logistic regression analysis of risk factors asso-
ciated with lower MMSE scores is shown in Table 5.
After adjusting for covariates, HD treatment (OR = 2.28,
Table 2 Age-specific prevalence of lower Mini-Mental
State Examination (MMSE) scores (<24) in patients with
hemodialysis and the general population in Japan
Age group Patients on hemodialysis Controls
% ± SD n/N % ± SD n/N
30-39 years old 12.5 ± 11.7 1/8 1.3 ± 1.3 1/75
40-49 years old 0.0 ± 0.0 0/14 0.7 ± 0.7 1/144
50-59 years old 8.7 ± 5.9 2/23 2.5 ± 1.0 6/239
60-69 years old 16.3 ± 5.3 8/49 8.7 ± 1.9 20/229
70-79 years old 29.3 ± 7.1 12/41 13.6 ± 2.8 21/154
80+ years old 31.6 ± 10.7 6/19 18.2 ± 11.6 2/11
Table 3 Gender-specific prevalence (%) of lower MMSE
scores (<24)
Sex Patients on hemodialysis Controls
% ± SD n/N % ± SD n/N
Male* 15.9 ± 3.9 14/88 8.0 ± 1.5 25/314
Female* 22.7 ± 5.2 15/66 4.8 ± 0.9 26/538
The obtained data were analyzed using a c
2 test or Fisher’s exact test
between HD patients and controls.
*Indicates a significant difference (P <0.05) between groups.
Table 4 Prevalence (%) of lower Mini-Mental State
Examination (MMSE) scores (<24) among participants
segregated according to educational level
Age group Patients on hemodialysis Controls
% ± SD n/N % ± SD n/N
1-9 years* 29.2 ± 5.6 19/65 14.3 ± 2.1 38/266
10-12 years* 13.9 ± 4.1 10/72 2.6 ± 0.7 12/460
13+ years 0 ± 0 0/17 0.7 ± 0.7 1/147
The obtained data were analyzed using a c
2 test or Fisher’s exact test
between HD patients and controls.
*Indicates a significant difference (P <0.05) between groups.
Table 5 Risk factors associated with having lower Mini-
Mental State Examination (MMSE) scores (<24) estimated
by logistic regression analysis
Independent variables Odds ratio 95% CI P value
Age 1.05 1.02 to 1.08 0.01
Gender 1.52 0.93 to 2.50 0.098
Duration of education (years) 0.76 0.66 to 0.86 0.001
Hemodialysis 2.28 1.33 to 3.94 0.01
The multiple logistic regression model included all of the above-mentioned
factors as independent variables.
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risk factor. Murray et al. [5] showed a higher risk (odds
ratio = 3.54) of having severe cognitive impairment
among HD patients compared to non-HD controls.
They assessed cognitive function across three cognitive
domains: memory, executive function, and language,
using nine validated neuropsychological tests. Their
odds ratio was higher than that of our study, possibly
due to differences in the neuropsychological tests used.
Our results do not mean that HD treatment itself is a
risk factor for cognitive impairment, because the dura-
tion of HD does not have significant relationship to
MMSE scores. A previous study [22] showed that lower
estimated glomerular filtration rate (eGFR) relates to
lower cognitive function in chronic kidney disease
(CKD) patients. Cognitive impairment of HD patients
might be due to CKD prior to kidney failure.
Previous studies have shown a relationship between
cerebrovascular disease and cognitive impairment
[23,24]. The prevalence of stroke in the United States
Renal Data System (USRDS) HD population is 17%,
compared with 4% in the general Medicare population
[25]. The proportion experiencing a stroke each year is
almost as high; the incidence is 15% for HD patients
and 2.4% for the non-chronic kidney disease population.
Stroke is also 6-9 times more common in hospitalized
HD patients than in non-HD patients [26]. HD patients
without cerebrovascular disease in Japan had a lower
prevalence of dementia (7.2%) than did HD patients
with cerebrovascular disease (23.1%) [1]. In this study,
the incidence having lower MMSE scores (<24) is 34.6%
(9/26) for HD patients with cerebrovascular disease and
15.6% (20/128) for HD patients without cerebrovascular
disease population. Although cerebrovascular disease
might explain a part of the cognitive impairment among
HD patients, it could not fully explain all causes of their
impairment.
We also found a relationship (P = 0.05) between hypo-
natremia and the MMSE score among HD patients. This
relationship was also reported in a previous study by
Maugeri et al. [14]. Hyponatremia depends on various
factors including blood dilution by chronic fluid over-
load and dietary sodium restriction [27]. These factors
might explain why no correlations were observed with
other blood parameters, which are stabilized by HD to
some extent.
There are several limitations to our study. First, we
administered only the MMSE for assessing the cognitive
function. Although the MMSE is suitable for screening
of some cognitive functions including orientation to
place and time, short-term memory, episodic long-term
memory, subtraction and attention, the MMSE score
does not always reflect the cognitive function exactly; it
is known to sometimes be influenced by the education
level of the subject. Improved detection of cognitive
impairment among HD patients is required in future
studies. Second, this was a cross-sectional study; thus,
associations between HD and cognitive impairment sug-
gest, but do not provide evidence for a causal relation.
It is necessary to conduct a longitudinal study to clarify
the reason for impaired cognition in HD patients. Third,
not all possible parameters were included in this study
such as dietary habits, atherosclerosis, genetic factors
and medications. Further investigation including impor-
tant confounders is required.
Conclusions
This report describes the largest study to date assessing
the effect of HD on cognitive function and the first
report comparing cognitive function between HD
patients and the general population in Japan. We found
that HD treatment was an independent risk factor for
cognitive impairment. In addition, serum sodium level,
dry weight and history of cerebrovascular disease tended
to associate with MMSE score among HD patients.
There is a high prevalence of cognitive impairment
among HD patients that has adverse implications for
hospitalization and reduced life expectancy. Therefore,
cognitive impairment in HD patients should be moni-
tored carefully and treated in an appropriate manner.
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Table 6 Risk factors associated with having lower Mini-
Mental State Examination (MMSE) scores (<24) estimated
by logistic regression analysis
Independent variables Odds ratio 95% CI P value
Age 1.01 0.95 to 1.06 0.830
Gender 1.42 0.36 to 5.56 0.619
Amount of education (years) 0.74 0.57 to 0.97 0.05
Duration of hemodialysis (years) 1.03 0.93 to 1.13 0.608
Erythrocyte count (10
4/mm
3) 1.00 0.98 to 1.01 0.537
Albumin (g/dl) 1.54 0.37 to 6.37 0.549
Sodium (mEq/l) 0.86 0.74 to 1.00 0.05
Potassium (mEq/l) 0.77 0.33 to 1.83 0.558
Uric acid (mg/dl) 0.79 0.52 to 1.20 0.265
Creatinine (mg/dl) 0.95 0.75 to 1.21 0.681
Blood urea nitrogen (mg/dl) 1.01 0.97 to 1.05 0.578
Dry weight (kg) 0.94 0.88 to 1.00 0.061
Amount of hemodialysis (Kt/V) 0.27 0.06 to 1.36 0.113
History of diabetes mellitus 2.07 0.66 to 6.46 0.211
History of hypertension 2.04 0.76 to 5.48 0.157
History of heart disease 1.16 0.34 to 4.02 0.810
History of cerebrovascular disease 3.07 0.98 to 9.66 0.055
The multiple logistic regression model included all above-mentioned factors
as independent variables.
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